A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins
Watanabe T, Ando K, Daidoji H, Otaki Y, Sugawara S, Matsui M, Ikeno E, Hirono O, Miyawaki H, Yashiro Y, Nishiyama S, Arimoto T, Takahashi H, Shishido T, Miyashita T, Miyamoto T, Kubota I, CHERRY study investigators
Journal of cardiology · 133 citations
Review labels
Neutral facts our review recorded about how this study was done. They describe method, never whether we like the result.
How it was studied
- Design
- Randomized controlled trial (indexed by PubMed)
- Studied in
- People
- Main outcome
- Health markers and function
Who paid for it
- Funding
- Funding not disclosed
Publication
- Published
- 2017-09-01 · J Cardiol · vol. 70 · issue 6 · pp. 537–544
- Publisher
- Elsevier BV
- Cited
- 179 citations · more than 99% of similar papers · 7.9× the field average
- Impact
- Top 10% most cited in its field
- References
- 39 works
- Access
- Open access (hybrid journal) · CC-BY-NC-ND
- Research areas
- Fatty Acid Research and Health · Lipoproteins and Cardiovascular Health · Eicosanoids and Hypertension Pharmacology
- Keywords
- Medicine, Internal medicine, Eicosapentaenoic acid, Cardiology, Percutaneous coronary intervention, Intravascular ultrasound, Myocardial infarction
- MeSH
- humans, quinolines, eicosapentaenoic acid, hydroxymethylglutaryl-coa reductase inhibitors, combined modality therapy, aged, middle aged, female, male, acute coronary syndrome, plaque, atherosclerotic, angina, stable, percutaneous coronary intervention
17 authors
From JP
- Tetsu Watanabe · correspondingYamagata University
- Kaoru AndoYamagata University
- Hyuma DaidojiYamagata Prefectural Central Hospital
- Yoichiro OtakiYamagata University
- Shigeo SugawaraNihonkai General Hospital
- Motoyuki MatsuiYamagata Prefectural Central Hospital
Abstract
Background
There is a residual risk of coronary heart disease (CHD) despite intensive statin therapy for secondary prevention. The aim of this study was to investigate whether coronary plaque regression and stabilization are reinforced by the addition of eicosapentaenoic acid (EPA) to high-dose pitavastatin (PTV).
Methods
We enrolled 193 CHD patients who underwent percutaneous coronary intervention (PCI) in six hospitals. Patients were randomly allocated to the PTV group (PTV 4mg/day, n=96) or PTV/EPA group (PTV 4mg/day and EPA 1800mg/day, n=97), and prospectively followed for 6-8 months. Coronary plaque volume and composition in nonstenting lesions were analyzed by integrated backscatter intravascular ultrasound (IB-IVUS).
Results
The PTV/EPA group showed a greater reduction in total atheroma volume compared to PTV group. IB-IVUS analyses revealed that lipid volume was significantly decreased during follow-up period in only PTV/EPA group. The efficacy of additional EPA therapy on lipid volume reduction was significantly higher in stable angina pectoris (SAP) patients compared to acute coronary syndrome patients. EPA/AA ratio was significantly improved in PTV/EPA group compared to PTV group. There was no significant difference in the incidence of major adverse cardiovascular events and side effects.
Conclusions
Combination EPA/PTV therapy significantly reduced coronary plaque volume compared to PTV therapy alone. Plaque stabilization was also reinforced by EPA/PTV therapy in particular SAP patients. The addition of EPA is a promising option to reduce residual CHD risk under intensive statin therapy.
Abstract via Europe PMC. Copyright remains with the authors or publisher (CC BY-NC-ND).
Community trust
Loading…
How much do you trust this study's findings?
Comments
Sign in to rate, comment on or flag this study.Sign inSomething wrong here?
Flag this study if its information, labels or funding look wrong. An editor reviews every flag.
Sign in to rate, comment on or flag this study.Sign inEducational information about published research. Not medical advice, and not a recommendation to start or stop anything.